Koufakis, Theocharis
Liberopoulos, Evangelos N.
Kokkinos, Alexander
Zebekakis, Pantelis
Kotsa, Kalliopi
Article History
Accepted: 19 February 2023
First Online: 21 March 2023
Declarations
:
: No external funds were used in the preparation of this article.
: TK has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Pharmaserve Lilly, and Novo Nordisk, for advisory boards from Novo Nordisk, and has participated in sponsored studies by Eli-Lilly and Novo Nordisk. ENL has participated in educational, research, and advisory activities sponsored by AstraZeneca, MSD, Lilly, Bayer, Amgen, Sanofi, Boehringer-Ingelheim, Novartis, Novo Nordisk, and Servier. AK has received grants through his institution and consulting fees from Novo Nordisk, Pharmaserve Lilly, and Elpen Pharmaceuticals, as well as consulting fees from Astra Zeneca, MSD, Sanofi, Bausch Health, Ethicon, Galenica Pharma, and Epsilon Health. None is related to the work presented herein. KK has received honoraria for lectures/advisory boards and research support from Astra Zeneca, Boehringer Ingelheim, Pharmaserve Lilly, Sanofi-Aventis, ELPEN, MSD, and Novo Nordisk. PZ has no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: TK reviewed the literature and drafted the first version of the manuscript. ENL, AK, PZ, and KK reviewed the literature and edited the manuscript. All authors have read and approved the final version of the manuscript.